Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ViroPharma gets FDA nod for Cinryze plant expansion at last

This article was originally published in Scrip

Executive Summary

ViroPharma has secured US FDA approval for expanded manufacturing of Cinryze (human C1 esterase inhibitor), under a supplement to its BLA for industrial scale manufacturing changes. The firm had previously had two knockbacks from the agency in the form of complete response letters in 2010 and earlier this year (scripintelligence.com, 8 February 2012). The manufacturing expansion at a site in the Netherlands is needed to meet rising US demand for the product, and will enable it to "to ensure the market is fully served and build adequate safety stock levels", said COO Dan Soland. The added industrial scale process will also give it the flexibility to increase production further still through additional shifts if necessary, he noted. Cinryze has been available in the US for the prevention of angioedema attacks in patients with hereditary angioedema since 2008. In Europe it was approved last year for a broader treatment and prevention indication. Production for the European market is located at a separate site.

You may also be interested in...



Big Pharma’s Aging Antibodies Cling To Their Crowns

The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?

Novartis To Pay $9.7bn For The Medicines Company

Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.

Deal Watch: Molecular Templates Aligns With Vertex On Optimizing Stem Cell Candidates

Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.

Topics

UsernamePublicRestriction

Register

SC018402

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel